FindTrial
Sign In

In vitro radiation dosimetry study of 177Lu-PSMA in the treatment of metastatic prostate cancer

In vitro radiation dosimetry study of 177Lu-PSMA in the treatment of metastatic prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114735
Enrollment
Unknown
Registered
2025-12-17
Start date
2025-12-23
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinically or radiographically diagnosed metastatic prostate cancer

Interventions

Observation group:None

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Hospitalized with 177Lu-PSMA-617; 2.Peripheral dose equivalent rate data during hospitalization are available;

Exclusion criteria

Exclusion criteria: 1.Patients with incomplete peripheral dose equivalent rate measurement;

Design outcomes

Primary

MeasureTime frame
Peripheral dose equivalent rate;—

Countries

China

Contacts

Public ContactYan Xing

Shanghai General Hospital

xy.1@163.com+86 21 3612 6600

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026